← Leaderboards
Hing C. Wong
Altor Bioscience Corporation
$14,637,090
Attributed
$14,637,090
Total exposure
15
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2005–16$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$14,637,090 · 15
By mechanism
R44$13,128,094 · 6
R43$1,508,996 · 9
Top collaborators
No co-investigators on record.
Most similar at Altor Bioscience Corporation
Same institution · by research overlap
- Peter R Rhode$2,659,783
- Jack Owen Egan$2,190,388
Others in their field
Top investigators on “Chimeric Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- Mohamed H Sayegh · University Of Pennsylvania$26,754,200
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$26,234,170
- Robert A Wood · Johns Hopkins University$24,963,233
- Larry Arthur$22,516,306
- Anne Moscona · Mount Sinai School Of Medicine Of Nyu$17,953,641
Research focus
Chimeric ProteinsSmall Business Innovation Research GrantEvaluationComplexDrug KineticsCytokinePharmaceutical PreparationsExhibitsDoseCellsBaseMediatingPreclinical StudyBiologicalMalignant NeoplasmsSafetyTumorImmunotherapeutic AgentPlayImmunotherapyImmuneImmune ResponseChemotherapyClinical Trials
Grant awards (25)
Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma$966,343
R44 · FY2016 · CA · contact PI
Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma$961,768
R44 · FY2015 · CA · contact PI
IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma$750,000
R44 · FY2015 · CA · contact PI
Novel IL-15 Superagonist Therapy for Bladder Cancer$598,323
R44 · FY2015 · CA · contact PI
IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma$750,000
R44 · FY2014 · CA · contact PI
Novel IL-15 Superagonist Therapy for Bladder Cancer$598,323
R44 · FY2014 · CA · contact PI
Tissue Factor Antagonists for ALI/ARDS$1,062,358
R44 · FY2013 · HL · contact PI
Tissue Factor Antagonists for ALI/ARDS$1,062,358
R44 · FY2012 · HL · contact PI
CD20-targeted IL-15 immunotherapeutic for B-cell malignancies$257,303
R43 · FY2012 · CA · contact PI
IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma$231,853
R43 · FY2012 · CA · contact PI
Tissue Factor Antagonists for ALI/ARDS$1,062,358
R44 · FY2011 · HL · contact PI
Bifunctional T cell receptor based immunotherapeutics$979,275
R44 · FY2011 · CA · contact PI
Evaluating Relevant Vaccine Epitopes Displayed on HIV-Infected Cells$237,181
R43 · FY2011 · AI · contact PI
Novel IL-15 Superagonist Therapy for Bladder Cancer$225,279
R43 · FY2011 · CA · contact PI
Bifunctional T cell receptor based immunotherapeutics$990,016
R44 · FY2010 · CA · contact PI
Bifunctional T cell receptor based immunotherapeutics$1,000,000
R44 · FY2009 · CA · contact PI
Creation of TCR-based Immunotherapeutic Targeting HIV-1$164,000
R43 · FY2009 · AI · contact PI
Transgenic Plant Technology for Producing Therapeutic Recombinant Antibodies$706,899
R44 · FY2007 · CA · contact PI
Transgenic Plant Technology for Producing Therapeutic Recombinant Antibodies$528,050
R44 · FY2006 · CA · contact PI
Bifunctional T cell receptor based immunotherapeutics$569,336
R44 · FY2005 · CA
Bifunctional T cell receptor based immunotherapeutics$542,687
R44 · FY2004 · CA
Soluble T-cell receptor based tumor screening reagents$100,000
R43 · FY2004 · CA
T-cell receptor based therapeutics for cytomegalovirus$100,000
R43 · FY2003 · AI
Bifunctional T cell receptor based immunotherapeutics$100,000
R43 · FY2002 · CA
T CELL RECEPTOR-BASED IMMUNOTHERAPEUTICS FOR CANCER$93,380
R43 · FY2001 · CA